Srdan Verstovsek, MD, on Predicting Resistance to Hydroxyurea Therapy in Polycythemia Vera
By Leah Sherwood, Srdan Verstovsek, MD, PhD - Last Updated: December 20, 2022Srdan Verstovsek, MD, of the MD Anderson Cancer Center, speaks on a study that used machine learning to predict resistance to hydroxyurea therapy in patients with polycythemia vera. Dr. Verstovsek and colleagues presented the study’s results at the 2022 American Society of Hematology Annual Meeting.
Post Tags:ASH22
Advertisement
Related Posts
RNA sequencing showed decreased gene expression levels of the NF-κB target genes IL1β and IER3 after emavusertib treatment.
The meeting had more than 2,500 registrants attending in person or online.
Researchers conducted interviews to gather the perspectives of both clinicians and nurses.
Nitin Jain, MD, joins Chadi Nabhan, MD, MBA, FACP, Host of The HemOnc Pulse, to discuss unmet needs in CLL.
Researchers conducted a cross-sectional survey of patients with multiple myeloma to address the question.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.